Cyclacel Pharma (CYCC) Tops Q2 EPS by 8c

Cyclacel Pharma (NASDAQ: CYCC) reported Q2 EPS of ($0.46), $0.08 better than the analyst estimate of ($0.54).

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Bernstein SocGen Group Upgrades X-Fab Silicon Foundries SE (XFAB:FP) to Outperform
• AeroVironment restates quarterly financials, citing $89M goodwill error